Titan, with a low stock price, large potential commercial market and enough cash on hand, has all the ingredients for a beautiful run up into the advisory panel.

Messier is long Titan shares.
Mark Messier is the founder of BioRunUp.com. Messier is a DOJ-certified Criminal Intelligence Analyst and former IT professional, specializing in law enforcement applications. In 2008, Messier began trading biotech stocks, using his analytical expertise to detect and capitalize on human and market patterns. Starting with only $2,200 in his trading account, he has booked over $400,000 in profit in just 4 years. In April 2010, Messier founded the subscription-based stock-trading web site BioRunUp.com to share his biotech trading ideas with the online investor community. Messier enjoys spending time with his wife and two young boys and visiting his "home away from home" in Costa Rica.

If you liked this article you might like

Analysts' Actions -- American Eagle, Mattel, Netflix, Tesaro and More

5 Stocks Under $10 Set to Soar

Titan Pharmaceuticals (TTNP) Stock Soars on FDA Committee Treatment Approval

4 Biotech Stocks Under $10 to Trade for Big Breakouts

Titan Pharma Opioid Addiction Implant Passes Key Study Hurdle